Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis
Authors:
- 9 November 2012
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 48 (1) , 78-87
Abstract
Objectives. Recent epidemiological studies suggest that metformin treatment may reduce the risks of cancer and overall cancer mortality among patients with diabetes mellitus (DM). However, data on hepatocellular carcinoma (HCC) are very limited and inconsistent. This meta-analysis was designed to pool data currently available to determine the association between metformin use and HCC among diabetic patients. Methods. The Medline and Embase databases were searched to identify the relevant studies between January 1966 and December 2011. The overall analysis was derived using a random-effects meta-analysis model (DerSimonian and Laird method). Subgroup analysis was performed to explore the source of heterogeneity and validate the results from overall analysis. The Newcastle-Ottawa Quality assessment scales were adopted for quality assessment; Begg's funnel plot and Egger's regression asymmetry test were used to detect the publication bias. Results. A total of seven studies were identified, including three cohort studies and four case-control studies. Based on the available data, the overall prevalence of HCC was 3.40% (562/16,549) in DM patients. The overall analysis showed a significantly reduced risk of HCC in metformin users versus nonusers in diabetic patients (relative risk (RR) 0.24, 95% confidence interval (CI) 0.13–0.46, p < 0.001). Fifteen subgroup analyses were performed, and most of them (12/15 = 80%) provided supporting evidence for the results of overall analysis. Begg's (Z = –0.15, p = 0.8819) and Egger's test (t = –0.79, p = 0.468) showed no significant risk of having a publication bias. Conclusion. Metformin treatment was associated with reduced risk of HCC in diabetic patients. To clarify this relationship, more high-quality studies are required.Keywords
This publication has 53 references indexed in Scilit:
- Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohortDiabetology & Metabolic Syndrome, 2011
- Cancer Risk Associated with Insulin Glargine among Adult Type 2 Diabetes Patients – A Nationwide Cohort StudyPLOS ONE, 2011
- Understanding the benefit of metformin use in cancer treatmentBMC Medicine, 2011
- Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individualsBMC Cancer, 2011
- Metformin and Other Biguanides in Oncology: Advancing the Research AgendaCancer Prevention Research, 2010
- AMPK As a Metabolic Tumor Suppressor: Control of Metabolism and Cell GrowthFuture Oncology, 2010
- Antidiabetic Therapies Affect Risk of Pancreatic CancerGastroenterology, 2009
- Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitisAlimentary Pharmacology & Therapeutics, 2008
- Measuring inconsistency in meta-analysesBMJ, 2003
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986